XTRA:BAYNPharmaceuticals
Bayer ASCO 2026 Oncology Data Puts NUBEQA And Valuation In Focus
Bayer plans to present 16 oncology abstracts at the 2026 ASCO Annual Meeting.
Primary results from multiple cancer trials, including several Phase II studies, are set to be shared.
The company will reveal head to head data from the Phase II ARACOG (AFT-47) trial of NUBEQA versus enzalutamide in advanced prostate cancer.
Additional safety, efficacy, and subgroup analyses will cover a range of Bayer cancer therapies.
Bayer (XTRA:BAYN), trading at around €36.53, has had mixed share...